Neurocrine Biosciences, Inc NASDAQ:NBIX:

  • NEUROCRINE BIOSCIENCES INITIATES PHASE 2 STUDY OF CRINECERFONT IN PEDIATRIC PATIENTS UNDER 4 YEARS OLD WITH CLASSIC CONGENITAL ADRENAL HYPERPLASIA